Related Experiment Videos
HIV-1 vaccine candidate evaluation in non-human primates
Y Lu1
1Institute for International Vaccine Development, Inc., Cambridge, MA 02138, USA.
Critical Reviews in Oncogenesis
|January 1, 1997
Summary
This review summarizes 13 years of industrial HIV-1 vaccine research, focusing on non-human primate studies. It details various vaccine types tested, including viral vectors and DNA vaccines, against challenge viruses.
Area of Science:
- Immunology
- Vaccinology
- Primate Models
Background:
- Industrial HIV-1 vaccine development over 13 years has primarily utilized non-human primate models.
- Evaluating vaccine efficacy in primates is crucial for advancing human immunodeficiency virus type 1 (HIV-1) vaccine candidates.
Purpose of the Study:
- To review HIV-1 vaccine candidates tested in chimpanzees and monkeys.
- To provide context on challenge viruses used in efficacy studies.
Main Methods:
- Comprehensive literature review of HIV-1 vaccine studies in non-human primates.
- Categorization of vaccine candidates including recombinant proteins, viral/bacterial vectors, DNA vaccines, and inactivated viruses.
- Inclusion of challenge virus information for efficacy study interpretation.
Main Results:
- Multiple vaccine platforms have been evaluated in non-human primates.
- Data on various immunogens (gp120, gp160, V3 peptide) and delivery systems were compiled.
- Information on challenge strains aids in understanding study outcomes.
Conclusions:
- Non-human primates remain a key model for preclinical HIV-1 vaccine evaluation.
- Diverse vaccine strategies have been explored, informing future development.
- Understanding challenge viruses is essential for interpreting vaccine efficacy data.